Class information for:
Level 1: ERCC1//RRM1//MED OVARIAN CANC SECT

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
17170 550 37.6 89%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
823 11253 NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ERCC1 Author keyword 122 48% 34% 186
2 RRM1 Author keyword 54 66% 9% 50
3 MED OVARIAN CANC SECT Address 19 74% 3% 14
4 EXCISION REPAIR CROSS COMPLEMENTATION 1 Author keyword 12 86% 1% 6
5 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 Author keyword 7 50% 2% 10
6 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 ERCC1 Author keyword 6 71% 1% 5
7 CLASS III BETA TUBULIN Author keyword 5 25% 3% 17
8 ERCC 1 Author keyword 4 40% 1% 8
9 EXCISION REPAIR CROSS COMPLEMENTING 1 Author keyword 3 57% 1% 4
10 PROGRAM THORAC ONCOL Address 3 50% 1% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ERCC1 122 48% 34% 186 Search ERCC1 Search ERCC1
2 RRM1 54 66% 9% 50 Search RRM1 Search RRM1
3 EXCISION REPAIR CROSS COMPLEMENTATION 1 12 86% 1% 6 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+1
4 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 7 50% 2% 10 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1
5 EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 ERCC1 6 71% 1% 5 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1+ERCC1 Search EXCISION+REPAIR+CROSS+COMPLEMENTATION+GROUP+1+ERCC1
6 CLASS III BETA TUBULIN 5 25% 3% 17 Search CLASS+III+BETA+TUBULIN Search CLASS+III+BETA+TUBULIN
7 ERCC 1 4 40% 1% 8 Search ERCC+1 Search ERCC+1
8 EXCISION REPAIR CROSS COMPLEMENTING 1 3 57% 1% 4 Search EXCISION+REPAIR+CROSS+COMPLEMENTING+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTING+1
9 RIBONUCLEOTIDE REDUCTASE M1 3 50% 1% 4 Search RIBONUCLEOTIDE+REDUCTASE+M1 Search RIBONUCLEOTIDE+REDUCTASE+M1
10 EXCISION REPAIR CROSS COMPLEMENTING GENE 1 2 44% 1% 4 Search EXCISION+REPAIR+CROSS+COMPLEMENTING+GENE+1 Search EXCISION+REPAIR+CROSS+COMPLEMENTING+GENE+1

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ERCC1 EXPRESSION 57 61% 11% 60
2 FLUOROURACIL CHEMOTHERAPY 45 48% 12% 68
3 ERCC1 26 26% 15% 84
4 RRM1 22 67% 4% 20
5 COMPLEMENTATION GROUP 1 20 62% 4% 21
6 TRIAL BIOLOGIC PROGRAM 9 67% 1% 8
7 ENDONUCLEASE ERCC1 XPF 4 33% 2% 11
8 III BETA TUBULIN 4 12% 6% 32
9 REDUCTASE M1 GENE 4 56% 1% 5
10 CHROMOSOME SEGMENT 11P155 3 43% 1% 6

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC 2011 86 57 33%
ERCC1 and RRM1: Ready for Prime Time? 2013 25 57 56%
Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? 2014 13 85 27%
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer 2011 48 74 34%
Prognostic Role of ERCC1 in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis 2011 30 34 47%
Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature 2009 52 36 56%
Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer 2011 20 75 41%
Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis 2012 20 18 33%
Predictive Role of Repair Enzymes in the Efficacy of Cisplatin Combinations in Pancreatic and Lung Cancer 2014 4 44 27%
The role of beta III tubulin in predicting chemoresistance in non-small cell lung cancer 2010 28 53 36%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MED OVARIAN CANC SECT 19 74% 2.5% 14
2 PROGRAM THORAC ONCOL 3 50% 0.7% 4
3 MED BRANCHNIH 2 67% 0.4% 2
4 PATHOL 5442 2 50% 0.5% 3
5 INSERM CANC POPULAT ER3 1 100% 0.4% 2
6 IMMUNOL HEMOPATHIES 1 40% 0.4% 2
7 MED BRANCH CLIN SCINIH 1 40% 0.4% 2
8 CLIN PHARMACOL NEW DRUG DEV UNIT 1 33% 0.4% 2
9 DANISH BREAST CANC COOPERAT GRP DBCG REGISTRY 1 50% 0.2% 1
10 DEV THER EUT MED BRANCH 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000228063 XRCC1//XRCC3//XRCC1 GENE
2 0.0000141524 THYMIDYLATE SYNTHASE//DIHYDROPYRIMIDINE DEHYDROGENASE//OROTATE PHOSPHORIBOSYL TRANSFERASE
3 0.0000135381 CISPLATIN RESISTANCE//PLATINUM DNA ADDUCTS//HUMAN OVARIAN CANCER CELL LINE
4 0.0000118397 GEMCITABINE//TROXACITABINE//DEOXYCYTIDINE KINASE
5 0.0000113582 PHILIP MORRIS INT RD//COMPUTAT PL GENOM PROGRAM//SECT COMPUTAT BIOMED
6 0.0000100426 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
7 0.0000088507 TUBULIN ISOTYPES//TYROSINATION//DETYROSINATION
8 0.0000085385 GEFITINIB//ERLOTINIB//EGFR MUTATION
9 0.0000083565 XERODERMA PIGMENTOSUM//COCKAYNE SYNDROME//NUCLEOTIDE EXCISION REPAIR
10 0.0000078816 N2 DISEASE//PLEURAL INVASION//STAGE IIIA